New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
09:02 EDTACTGAcacia reaches settlement with Mallinckrodt over Exalgo
Actavis announced that it has reached a settlement with Mallinckrodt on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo tablets. In January of 2012, Actavis and Mallinckrodt previously settled litigation involving the 8 mg, 12 mg and 16 mg dosage strengths of the product. Under terms of the settlement agreement, Mallinckrodt has granted Actavis a royalty-free license to U.S. patents relating to Exalgo to sell Actavis' 32 mg product starting on May 15, 2014. Other details of the settlement were not disclosed.
News For ACTG From The Last 14 Days
Check below for free stories on ACTG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
11:28 EDTACTGAcacia Research, InterDigital slip after appeals court vacates VirnetX award
Subscribe for More Information
September 11, 2014
06:03 EDTACTGAcacia Research subsidiary reaches settlement with Fujitsu Network Communication
Subscribe for More Information
September 5, 2014
06:04 EDTACTGAcacia Research enters into settlement agreement with Kaba Ilco, Kaba Holding
Acacia Research announced that its O.S. Security LLC subsidiary has entered into a settlement agreement with Kaba Ilco Corporation and Kaba Holding AG. The agreement resolves litigation that was pending in the United States District Court for the Central District of California.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use